Key features and details | |
Cat. No. | MABL-1303 |
Name | Anti-CXCR3 mAbs |
Clone No. | AFD- 9C5 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | FC, ELISA |
Species Reactivity | Marmoset, Human, Mouse |
Basic Information | |
Specificity | This antibody strongly binds human, mouse and marmoset CXCR3. Epitope mapping revealed that this antibody binds a peptide (FSSSYDYGENESDSCCTSPPCP) which corresponds to amino acid position 23-44 of the human CXCR3. |
Alternative Name | CD183; CXC-R3; CXCR-3; CKR-L2; IP-10 receptor; GPR9; C-X-C chemokine receptor type 3; G protein-coupled receptor 9; Interferon-inducible protein 10 receptor |
UniProt | P49682 |
Immunogen | The original antibody was generated by immunizing a CXCR3* knockout mice with LI.2 cells (a murine pre-B cell line) were transfected with the mouse CXCR3 gene. |
Application Notes | The binding of this antibody with CXCR3 from various species was assessed by flow cytometry. It was shown to recognize LI.2 cells transfected with mouse CXCR3 (mCXCR3) or human CXCR3 (hCXCR3), but not untransfected LI.2 cells or cells transfected with other chemokine receptors (i.e. mCXCR2) in flow cytometry. Epitope mapping of this antibody was performed using ELISA. To access the in vivo effect, various concentrations of the antibody were injected intraveneously in a mice. It was seen that the original 9C4, mouse IgG1 version, completely depleted CD4+CXCR3+, CD8+/CXCR3+ and B2207CXCR3+ cells at a concentration as low as 2 mg/kg (WO2014186842). Chimeric antibodies derived from 9C5 called 9C5-3MFc and 9C5-Fc-KO and humanized verion are also available on request. |
Antibody First Published | |
Note on publication | |
COA Information (For reference only, actual COA shall prevail) | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |